comparemela.com
Home
Live Updates
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas : comparemela.com
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.
Related Keywords
Dana Farber Cancer Institute ,
Massachusetts ,
United States ,
Boston ,
Tocilizumab Actemra ,
Lakshmi Nayak ,
Mono Pharmaceuticals ,
Wolters Kluwer Uptodate Inc ,
Harvard Medical School ,
Lymphoma At Dana Farber Cancer Institute ,
Kazia Therapeutics ,
comparemela.com © 2020. All Rights Reserved.